Trial Profile
Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2811376 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs LY 2811376 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
- 09 Mar 2009 New trial record